Likely place in therapy

Likely place in therapy

As with all biologic disease-modifying antirheumatic drugs (DMARDs) for ulcerative colitis and Crohn's disease, Remsima (subcutaneous) would be prescribed and started in secondary care gastroenterology clinics. Unlike intravenous infliximab, which is usually given in secondary care, Remsima (subcutaneous) can be self‑administered at home if the person, family member or carer has been given the appropriate training.

In practice Remsima (subcutaneous) is most likely to be used in people:

  • who are already established on intravenous infliximab

  • with stable disease but who have difficulty attending hospital appointments

  • for whom the risk of attending hospital for intravenous infusions outweighs the benefits.

It may also be beneficial for people who are starting on infliximab who have not used a biologic before, or who are switching from a biologic with a different mechanism of action from the TNF‑alpha inhibitors.

There are no data on people switching to Remsima (subcutaneous) from Remsima (intravenous) at administration frequencies higher than every 8 weeks, and there are no data on people switching from other infliximab products to Remsima (subcutaneous).